XELJANZ XR Drug Patent Profile

Which patents cover Xeljanz Xr, and when can generic versions of Xeljanz Xr launch?

Xeljanz Xr is a drug marketed by Pfizer and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and twenty-four patent family members in fifty-five countries.

The generic ingredient in XELJANZ XR is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeljanz Xr

A generic version of XELJANZ XR was approved as tofacitinib citrate by AJANTA PHARMA LTD on June 1^st, 2021.

Summary for XELJANZ XR

International Patents:	124
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELJANZ XR

Paragraph IV (Patent) Challenges for XELJANZ XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	22 mg	208246	1	2020-12-28
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	11 mg	208246	1	2016-11-07

US Patents and Regulatory Information for XELJANZ XR

XELJANZ XR is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	AB	RX	Yes	Yes	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	9,937,181*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	11,253,523*PED				Y

International Patents for XELJANZ XR

When does loss-of-exclusivity occur for XELJANZ XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XELJANZ XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095487
Australia	2014233850
Australia	2017203334
Brazil	112015020453

Supplementary Protection Certificates for XELJANZ XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1666481	132017000095300	Italy		PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1666481	PA2017025,C1666481	Lithuania		PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322
1666481	2017C/032	Belgium		PRODUCT NAME: TOFACITINIB; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324
1666481	LUC00031	Luxembourg		PRODUCT NAME: TOFACITINIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE SEL DE CITRATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324

XELJANZ XR: Patent Landscape and Investment Outlook

Last updated: February 19, 2026

XELJANZ XR, developed by Pfizer, is an extended-release formulation of tofacitinib citrate, a Janus kinase (JAK) inhibitor. The drug is approved for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. This analysis examines the patent landscape, market performance, and competitive environment to assess its investment potential.

What is the Current Patent Status of XELJANZ XR?

XELJANZ XR benefits from a robust patent portfolio designed to extend market exclusivity. The core composition of matter patent for tofacitinib, U.S. Patent No. 8,530,493, issued in 2013 and is currently set to expire on November 14, 2027. However, Pfizer has secured additional patents covering specific aspects of XELJANZ XR, including its extended-release formulation and methods of use.

Key patents of relevance include:

• U.S. Patent No. 9,687,427: This patent, titled "Extended Release Formulations of Tofacitinib," issued in 2017 and is scheduled to expire on October 11, 2031. It covers the specific pharmaceutical composition that enables the once-daily dosing of XELJANZ XR.
• U.S. Patent No. 10,493,022: This patent, also covering extended-release formulations, is set to expire on October 11, 2031.
• U.S. Patent No. 10,525,017: This patent relates to methods of treating certain autoimmune diseases with extended-release tofacitinib and has an expiration date of October 20, 2031.
• U.S. Patent No. 10,905,715: This patent, concerning extended-release compositions, is set to expire on December 17, 2035.

These formulation and method-of-use patents are critical for extending XELJANZ XR's market exclusivity beyond the expiration of the original tofacitinib composition of matter patent. The strategic filing of these later-expiring patents aims to deter generic competition for the extended-release formulation.

What is the Market Performance of XELJANZ XR?

XELJANZ XR has demonstrated significant commercial success since its launch. Pfizer reported net sales for XELJANZ (including both immediate-release and extended-release formulations) of approximately $2.5 billion in 2022. The extended-release formulation, XELJANZ XR, is a primary driver of these sales due to its improved patient convenience.

Global XELJANZ Net Sales (USD Billions)

Year	Net Sales
2020	2.25
2021	2.46
2022	2.50

Source: Pfizer Annual Reports

The market for JAK inhibitors is competitive, but XELJANZ XR has maintained a strong position, particularly in rheumatoid arthritis. The drug's efficacy and the convenience of once-daily dosing contribute to its market share. However, increasing competition from other JAK inhibitors and biosimil biologics necessitates ongoing market analysis.

Who are the Key Competitors for XELJANZ XR?

The competitive landscape for XELJANZ XR is multi-faceted, comprising other JAK inhibitors and established biologic therapies.

Direct Competitors (Other JAK Inhibitors):

• Upadacitinib (Rinvoq) by AbbVie: Approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. Upadacitinib is a selective JAK1 inhibitor.
• Baricitinib (Olumiant) by Eli Lilly: Approved for rheumatoid arthritis, alopecia areata, and COVID-19. Baricitinib is a selective JAK1 and JAK2 inhibitor.
• Filgotinib (Jyseleca) by Gilead Sciences: Approved in Europe and Japan for rheumatoid arthritis and ulcerative colitis. Filgotinib is a selective JAK1 inhibitor.

Indirect Competitors (Biologics):

• TNF Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade) are long-standing treatments for inflammatory diseases. Many of these have biosimil versions available, increasing pricing pressure.
• Other Biologics: Tocilizumab (Actemra), Abatacept (Orencia) are also used in rheumatoid arthritis and other autoimmune conditions.

The competitive threat is amplified by the patent expiries of blockbuster biologics like Humira, leading to increased market penetration by biosimil versions. This pricing pressure can indirectly affect the market dynamics for all advanced therapies, including JAK inhibitors.

What are the Regulatory and Safety Considerations for XELJANZ XR?

XELJANZ XR, like all JAK inhibitors, carries specific boxed warnings from regulatory agencies, including the U.S. Food and Drug Administration (FDA). These warnings highlight increased risks of serious infections, mortality, cardiovascular events, thrombosis, and malignancy.

In August 2021, the FDA updated its boxed warnings for tofacitinib and other JAK inhibitors. These updates were based on findings from a post-marketing safety study (ORAL Surveillance) that investigated the risks associated with these drugs in patients with rheumatoid arthritis. The study showed an increased risk of major adverse cardiovascular events (MACE) and the development of certain cancers, including lymphomas and lung cancers, in patients treated with tofacitinib compared to TNF inhibitors.

These safety concerns have led to:

• Labeling changes: The drug's label now includes more prominent warnings and contraindications.
• Prescribing restrictions: In some cases, the FDA has recommended limiting the use of JAK inhibitors to patients who have failed or cannot tolerate at least one TNF inhibitor.
• Increased scrutiny: Regulatory bodies globally continue to monitor the safety profiles of JAK inhibitors.

These regulatory actions and safety considerations are critical for physician prescribing patterns and patient access, potentially impacting market growth and requiring ongoing pharmacovigilance by Pfizer.

What is the Outlook for Generic Competition?

The expiration of the U.S. Patent No. 8,530,493 on November 14, 2027, opens the door for generic competition of the immediate-release formulation of tofacitinib. However, XELJANZ XR's extended-release formulation is protected by later-expiring patents, as detailed previously, extending its exclusivity.

The earliest generic entry for XELJANZ XR would likely target the expiration of U.S. Patent No. 9,687,427 on October 11, 2031. This provides Pfizer with a significant period of market exclusivity for the extended-release product.

Generic manufacturers may challenge these formulation and method-of-use patents through Paragraph IV certifications under the Hatch-Waxman Act. Successful patent challenges could lead to earlier generic entry, but the complexity of extended-release formulations and method-of-use claims can present significant hurdles.

Factors influencing the timing and impact of generic competition include:

• Strength of XELJANZ XR patents: The validity and enforceability of Pfizer's formulation and method-of-use patents.
• ANDA filings and approvals: The number of Abbreviated New Drug Applications (ANDAs) filed and approved by the FDA.
• Litigation outcomes: Court rulings on patent infringement and validity challenges.
• Generic pricing strategies: The price points at which generic versions are launched.

While generic versions of tofacitinib citrate are expected to emerge, the extended-release formulation's patent protection provides a substantial buffer against widespread generic erosion for XELJANZ XR until at least 2031.

What are the Investment Fundamentals and Risks?

The investment case for XELJANZ XR rests on its established market position, continued sales growth driven by its convenient formulation, and extended patent protection. However, several risks warrant consideration.

Strengths:

• Established Market Presence: XELJANZ XR is a recognized and prescribed treatment for major autoimmune diseases.
• Differentiated Formulation: The once-daily extended-release formulation offers a clear patient convenience advantage.
• Pipeline and Portfolio Diversification: Pfizer's broader pipeline and portfolio can offset risks associated with any single product.
• Extended Patent Exclusivity: Key formulation patents provide a significant runway before generic entry.

Risks:

• Intensifying Competition: The JAK inhibitor class is highly competitive, with new entrants and next-generation molecules.
• Safety Profile and Regulatory Scrutiny: The boxed warnings and ongoing safety monitoring by regulatory agencies pose a persistent risk to market access and prescribing patterns.
• Biosimilar Competition for Biologics: The increasing availability of biosimil biologics can exert pricing pressure on the entire market for advanced autoimmune therapies.
• Patent Litigation: Future challenges to XELJANZ XR's formulation and method-of-use patents could lead to earlier generic entry.
• Therapeutic Shifts: Evolution in treatment paradigms may favor alternative mechanisms of action or novel therapies.

Financial Metrics:

Pfizer's financial reporting for XELJANZ is critical. Investors should monitor:

• Sales growth trajectory: Consistency of sales growth against market expectations and competitor performance.
• Profitability: The contribution of XELJANZ XR to Pfizer's overall profit margins.
• R&D investment: Pfizer's continued investment in the JAK inhibitor class and other therapeutic areas.

The investment outlook for XELJANZ XR is positive in the near to medium term, supported by its market penetration and patent exclusivity for the extended-release formulation. However, the long-term outlook will be shaped by the evolving competitive landscape, regulatory environment, and the success of Pfizer's ongoing pipeline development.

Key Takeaways

XELJANZ XR possesses significant commercial traction driven by its extended-release formulation. Pfizer has strategically protected this formulation with patents extending exclusivity beyond the original tofacitinib composition of matter patent. While facing intense competition from other JAK inhibitors and biologics, XELJANZ XR's market position is currently strong. However, its long-term prospects are subject to ongoing regulatory scrutiny regarding its safety profile and the eventual emergence of generic competition for its extended-release formulation.

Frequently Asked Questions

1. When does the primary patent for tofacitinib expire, and how does this impact XELJANZ XR? The core composition of matter patent for tofacitinib (U.S. Patent No. 8,530,493) expires on November 14, 2027. This impacts the immediate-release formulation of tofacitinib, allowing for generic entry. However, XELJANZ XR's extended-release formulation is protected by later-expiring patents.

2. What are the main safety concerns associated with XELJANZ XR? XELJANZ XR carries boxed warnings for increased risks of serious infections, mortality, cardiovascular events, thrombosis, and malignancy, based on post-marketing studies.

3. Which patents specifically protect the extended-release formulation of XELJANZ XR, and when do they expire? Key patents protecting the extended-release formulation include U.S. Patent No. 9,687,427 and U.S. Patent No. 10,493,022, both expiring on October 11, 2031, and U.S. Patent No. 10,905,715, expiring on December 17, 2035.

4. How does XELJANZ XR compare to other JAK inhibitors in terms of market share and safety profile? XELJANZ XR has maintained a significant market share, particularly in rheumatoid arthritis, due to its once-daily dosing. Competitors like Rinvoq and Olumiant also hold substantial market positions and share similar safety warnings, though specific risk profiles and approved indications may differ.

5. What is the potential impact of biosimilar competition on the market for XELJANZ XR? The increasing availability of biosimilar versions of established biologic therapies, particularly TNF inhibitors, exerts downward pricing pressure on the overall market for autoimmune treatments. This can indirectly influence the pricing and market dynamics for all advanced therapies, including XELJANZ XR, by increasing the cost-competitiveness of alternative treatment options.

Citations

[1] Pfizer Inc. (2023). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission. [2] United States Patent and Trademark Office. (n.d.). Patent Database Search. Retrieved from https://www.uspto.gov/patents [3] U.S. Food and Drug Administration. (2021, August 26). FDA Approves New Safety Warnings for JAK Inhibitors. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-safety-warnings-jak-inhibitors